Buscar en
Clínica e Investigación en Arteriosclerosis (English Edition)
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis (English Edition) Effect of resveratrol on seric vascular endothelial growth factor concentrations...
Journal Information
Vol. 30. Issue 5.
Pages 209-216 (September - October 2018)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 30. Issue 5.
Pages 209-216 (September - October 2018)
Original article
DOI: 10.1016/j.artere.2018.08.002
Effect of resveratrol on seric vascular endothelial growth factor concentrations during atherosclerosis
Efecto del resveratrol sobre las concentraciones séricas del factor de crecimiento endotelial vascular durante la aterosclerosis
Visits
...
Leticia Figueiraa,
Corresponding author
figueiraleticia@gmail.com

Corresponding author.
, Julio César Gonzáleza,b
a School of Bioanalysis, Laboratorio de Investigación y Postgrado de la Escuela de Bioanálisis (LIPEB) [Research and Postgraduate Laboratory of the School of Bioanalysis], Faculty of Health Sciences, Universidad de Carabobo, Naguanagua, Carabobo, Venezuela
b Laboratorio Clínico Julio César González, Valencia, Carabobo, Venezuela
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (3)
Table 1. Lipid profile in the study rabbits.
Table 2. Analysis of the Spearman correlation between the concentrations of vascular endothelial growth factor (VEGF), C-reactive protein (CRP) and the lipid profile.
Table 3. Distribution of the rabbits according to the maximum degree of atheroma found in the sections of aorta.
Show moreShow less
Abstract
Introduction

Although it is known that resveratrol has anti-inflammatory and anti-atherogenic actions, its effect on vascular endothelial growth factor (VEGF) in atherosclerosis is unknown.

Objective

To evaluate the effect of resveratrol on serum concentrations of VEGF during the progression and evolution of atherosclerosis, as well as and its evolution over time in rabbits fed with a cholesterol diet.

Materials and methods

A total of 48 New Zealand white male rabbits were randomly divided into four groups of 12 rabbits: group 1 (control): standard diet (commercial rabbit food); group 2: cholesterol diet (0.5% cholesterol); group 3 (control resveratrol): standard diet (commercial rabbit food) and resveratrol (2mg/kg); group 4: cholesterol diet (0.5% cholesterol) and resveratrol (2mg/kg), for 12weeks. Blood samples of overnight-fasted rabbits were collected at baseline and the sixth and twelfth weeks, and the lipid profile, VEGF, and C-reactive protein (CRP) levels were determined. Half of the animals were sacrificed on the sixth or twelfth week, and the aorta was dissected for histological studies.

Results

VEGF and CRP levels were significantly higher in groups 2 and 4 than in groups 1 and 3, respectively, from the 6th week (p<0.001). VEGF and CRP were significantly lower in group 4 than in group 2 on 12th week (p<0.004). Supplementation of resveratrol reduced the formation of atherosclerotic lesions.

Conclusions

Serum VEGF and CRP levels are early markers of atherosclerosis. Oral supplementation of resveratrol exerts anti-inflammatory and anti-atherosclerotic effects, decreasing serum concentrations of VEGF and CRP and the formation and evolution of atherosclerotic lesions.

Keywords:
Resveratrol
Vascular endothelial growth factor
C-reactive protein
Atherosclerosis
Inflammation
Resumen
Introducción

El resveratrol tiene propiedades antiinflamatorias y antiaterogénicas; sin embargo, se desconoce su efecto sobre el factor de crecimiento endotelial vascular (VEGF) en la aterosclerosis.

Objetivo

Evaluar el efecto del resveratrol sobre las concentraciones séricas del VEGF durante la progresión y evolución de la aterosclerosis y su evolución en el tiempo en conejos alimentados con dieta enriquecida con colesterol.

Materiales y métodos

Cuarenta y ocho conejos machos divididos en cuatro grupos de 12 conejos recibieron: grupo 1 (control): conejarina; grupo 2: conejarina suplementada con 0,5% colesterol; grupo 3 (control resveratrol): conejarina y resveratrol (2mg/kg); grupo 4: conejarina suplementada con 0,5% colesterol y resveratrol, durante 12 semanas. Se realizaron determinaciones séricas de triglicéridos, colesterol y sus fracciones, VEGF y proteína C reactiva (PCR) al inicio, a la 6.a y a la 12.a semana de experimentación. La mitad de los conejos fueron sacrificados a la 6.a y a la 12.a semana y se realizó estudio histológico de su aorta.

Resultados

El VEGF y la PCR aumentaron en los grupos 2 y 4 desde la 6.a semana de experimentación con respecto a los grupos 1 y 3, respectivamente (p<0,001). En la duodécima semana se observó una disminución de los niveles de VEGF y PCR en el grupo4 con respecto al grupo 2 (p<0,004). El tratamiento con resveratrol disminuyó la formación de ateromas.

Conclusiones

El VEGF y la PCR séricos constituyen marcadores tempranos no invasivos de inflamación y aterosclerosis. La suplementación oral de resveratrol ejerce efectos antiinflamatorios y antiateroscleróticos, disminuyendo las concentraciones séricas de VEGF y PCR, y la formación y evolución de las lesiones ateroscleróticas.

Palabras clave:
Resveratrol
Factor de crecimiento endotelial vascular
Proteína C reactiva
Aterosclerosis
Inflamación

Article

These are the options to access the full texts of the publication Clínica e Investigación en Arteriosclerosis (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Clínica e Investigación en Arteriosclerosis (English Edition)

Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 19,34 €

Comprar ahora
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.